Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1

Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish

(2010) N. Bolli et al.   BLOOD

Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

(2010) Warren Fiskus et al.   CANCER BIOLOGY & THERAPY

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

GSK-3 Promotes Conditional Association of CREB and Its Coactivators with MEIS1 to Facilitate HOX-Mediated Transcription and Oncogenesis

(2010) Zhong Wang et al.   CANCER CELL

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives

(2010) Brunangelo Falini et al.   CURRENT OPINION IN ONCOLOGY

IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

(2010) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY

Heat Shock Protein 90 Inhibition Depletes TrkA Levels and Signaling in Human Acute Leukemia Cells

(2010) Rekha Rao et al.   MOLECULAR CANCER THERAPEUTICS

The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model

(2009) K. Cheng et al.   BLOOD

Differentiation therapy of leukemia: 3 decades of development

(2009) D. Nowak et al.   BLOOD

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

(2009) W. Fiskus et al.   BLOOD

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA

(2009) A. K. Burnett et al.   BLOOD

NPM phosphorylation stimulates Cdk1, overrides G 2 /M checkpoint and increases leukemic blasts in mice

(2009) Wei Du et al.   CARCINOGENESIS

HOXA9 Modulates Its Oncogenic Partner Meis1 To Influence Normal Hematopoiesis

(2009) Y.-L. Hu et al.   MOLECULAR AND CELLULAR BIOLOGY

Acetylated NPM1 Localizes in the Nucleoplasm and Regulates Transcriptional Activation of Genes Implicated in Oral Cancer Manifestation

(2009) J. Shandilya et al.   MOLECULAR AND CELLULAR BIOLOGY

Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity

(2009) Y. Perera et al.   MOLECULAR CANCER THERAPEUTICS

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B

(2008) R. F. Schlenk et al.   HAEMATOLOGICA

Structural Consequences of Nucleophosmin Mutations in Acute Myeloid Leukemia

(2008) Charles G. Grummitt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dysregulation of the C/EBPα Differentiation Pathway in Human Cancer

(2008) Steffen Koschmieder et al.   JOURNAL OF CLINICAL ONCOLOGY

Transcription Regulation of the rRNA Gene by a Multifunctional Nucleolar Protein, B23/Nucleophosmin, through Its Histone Chaperone Activity

(2008) K. Murano et al.   MOLECULAR AND CELLULAR BIOLOGY

NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells

(2008) W Qi et al.   ONCOGENE